New insider activity at OptimizeRx ( (OPRX) ) has taken place on March 20, 2025.
Director James Paul Lang has made a significant investment in OptimizeRx by purchasing 321,408 shares of the company’s stock. This transaction is valued at an impressive $2,442,700, showcasing a strong vote of confidence in the company’s future prospects.
Recent Updates on OPRX stock
OptimizeRx Corporation has reported strong financial results for the fourth quarter and full year of 2024, with a 14% year-over-year increase in Q4 revenue and a 23% rise in gross profit. The company exceeded both its own guidance and Wall Street expectations, achieving a revenue of $92.1 million and an adjusted EBITDA of $11.7 million for the year. Despite a slight decline in cash reserves due to debt reduction efforts, OptimizeRx demonstrated significant cost savings and a high net revenue retention rate of 121%. Analysts have noted that the company’s strong performance is at odds with its conservative 2025 guidance, which anticipates at least $100 million in revenue. The positive earnings call highlighted the company’s strategic growth initiatives, including a focus on operational excellence and a transition to a subscription-based model, which are expected to drive future profitability and shareholder value.
More about OptimizeRx
YTD Price Performance: 73.13%
Average Trading Volume: 516,553
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $166.2M